• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    PROOF.pdf
    Size:
    124.9Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Abou-Alfa, G. K.
    Borbath, I.
    Cohn, A. L.
    Goyal, L.
    Lamarca, Angela
    Macarulla, T.
    Oh, D. Y.
    Roychowdhury, S.
    Sadeghi, S.
    Shroff, R. T.
    Howland, M.
    Li, A.
    Cho, T.
    Pande, A.
    Javle, M.
    Show allShow less
    Affiliation
    Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY,
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Background: Cholangiocarcinoma (CCA) treatment options are limited with a need to provide better disease control, improved outcome, and targeted therapy that is less toxic than standard chemotherapy. As the understanding of the molecular landscape of CCA has increased, the fibroblast growth factor receptor (FGFR) family has been found to play an important role in CCA. FGFR gene fusions and rearrangements represent driver mutations; they are present in 13e17% of intrahepatic CCA and may predict tumor sensitivity to FGFR inhibitors. Infigratinib (BGJ398) is an ATP-competitive, FGFR1e3 selective oral tyrosine kinase inhibitor. Based on promising preliminary response data of infigratinib in patients with relapsed/refractory CCA with FGFR2 gene fusions or other rearrangements (phase II trial CBJG398X2204), the PROOF trial is evaluating infigratinib vs gemcitabine + cisplatin in front-line patients with advanced CCA with FGFR2 gene rearrangements. Trial design: Patients with advanced/metastatic or inoperable CCA with FGFR2 gene fusions (determined by local or central laboratory) are randomized 2:1 to oral infigratinib once daily for 21 days of a 28-day treatment cycle vs intravenous standard gemcitabine (1000 mg/m2) + cisplatin (25 mg/m2) on days 1 and 8 of a 21-day cycle. Treatment will continue until confirmed progressive disease by central review, intolerance, withdrawal of informed consent, or death. Patients on the gemcitabine + cisplatin arm who develop disease progression can cross-over to receive infigratinib. The primary endpoint is progression-free survival (PFS, RECIST v1.1 central review). Secondary endpoints include overall survival, PFS (investigator determined), overall response rate, disease control rate, duration of response, and safety. Quality of life, pharmacokinetics and exploratory genetic alterations/biomarkers will also be measured. The trial will have sites in the US, EU, and APAC, including Australia. Enrollment is ongoing.
    Citation
    Abou-Alfa GK, Borbath I, Cohn AL, Goyal L, Lamarca A, Macarulla T, et al. 1014TiP PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements. Annals of Oncology. 2020;31:S701-S2.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/623469
    DOI
    10.1016/j.annonc.2020.08.1130
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2020.08.1130
    Type
    Meetings and Proceedings
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2020.08.1130
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.